News (167)

Transcript : UniQure N.V. - Special Call
UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease GL
UniQure Announces Update on Phase I/II Clinical Trials of AMT-130 Gene Therapy for the Treatment of Huntington’s Disease AQ
UniQure N : December 2023 Huntington's Disease Program Update AMT-130 PU
UniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease GL
UniQure Announces FDA Clearance of Investigational New Drug Application for AMT-191 Gene Therapy for Fabry Disease AQ
UniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs GL
UniQure Announces Strategic Reorganization to Reduce Operating Expenses and Support Advancement of Multiple Clinical-Stage Programs AQ
UniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy GL
UniQure Announces FDA Clearance of Investigational New Drug Application for AMT-260 Gene Therapy for Refractory Mesial Temporal Lobe Epilepsy AQ
UniQure Announces Second Quarter 2023 Financial Results and Highlights Recent Company Progress GL
UniQure Announces Leadership Addition to Support Advancement of Clinical Programs GL
UniQure N.V. Announces Executive Changes CI
Galapagos announces full year 2022 results and outlook for 2023 GL
Galapagos announces full year 2022 results and outlook for 2023 GL
Galapagos announces changes to Executive Committee GL
Galapagos announces changes to Executive Committee AQ
Galapagos NV Announces Changes in the Executive Committee Effective 1 January 2023 CI
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors GL
Galapagos announces CHMP adoption of PRAC’s recommendation for Jyseleca® following extensive safety review of all JAK inhibitors AQ
Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022 GL
Galapagos to present encouraging initial data from FILOSOPHY real-world arthritis study at ACR Convergence 2022 AQ
Transcript : Galapagos NV, Q3 2022 Earnings Call, Nov 04, 2022
Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress GL
Galapagos provides further insights into the treatment of ulcerative colitis at the upcoming United European Gastroenterology (UEG) Week 2022 congress AQ
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies GL
Galapagos receives positive CHMP opinion for Jyseleca® European label update based on testicular function safety data from MANTA/RAy studies AQ
Transcript : Galapagos NV, H1 2022 Earnings Call, Aug 05, 2022
Lebanon preparing to offer compromise on maritime spat with Israel, officials say RE
Galapagos : to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress - Form 6-K PU
Galapagos to showcase commitment to rheumatoid arthritis care at the upcoming European League Against Rheumatism congress GL
Transcript : Galapagos NV, Q1 2022 Earnings Call, May 06, 2022
Transcript : Galapagos NV, 2021 Earnings Call, Feb 25, 2022
Galapagos : provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress - Form 6-K PU
Galapagos provides further insights into the treatment of ulcerative colitis at the European Crohn’s and Colitis Organization (ECCO) annual congress AQ
Transcript : Galapagos NV Presents at JPMorgan 40th Annual Healthcare Conference, Jan-13-2022 08:15 AM
Galapagos : completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease - Form 6-K PU
Galapagos completes patient recruitment for MANGROVE Phase 2 trial with GLPG2737 in polycystic kidney disease AQ
Transcript : Galapagos NV, Q3 2021 Earnings Call, Nov 05, 2021
Galapagos : presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress (Form 6-K) PU
Galapagos : announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease (Form 6-K) PU
Galapagos : presents new data from the SELECTION Phase 3 program at the United European Gastroenterology Week (UEGW) 2021 congress AQ
Galapagos : announces completion of patient enrollment for DIVERSITY Phase 3 study with filgotinib in Crohn’s Disease AQ
GALAPAGOS : ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS (Form 6-K) PU
Galapagos : N.V., - GALAPAGOS ANNOUNCES POSITIVE CHMP OPINION FOR JYSELECA® (FILGOTINIB) FOR THE TREATMENT OF ADULTS WITH MODERATELY TO SEVERELY ACTIVE ULCERATIVE COLITIS PU
1234NextSee all

Companies (22)

INVESTOR AB 79 577 M $
Logo Investor AB

Investor AB is a Sweden-based industrial holding company. Its operations are divided into three business segments: Listed Core Investments, EQT and Patricia Industries. The Listed Core Investments segment consists of listed holdings, which embrace ABB, As ...

INVESTOR AB 79 577 M $
Logo Investor AB

Investor AB is a Sweden-based industrial holding company. Its operations are divided into three business segments: Listed Core Investments, EQT and Patricia Industries. The Listed Core Investments segment consists of listed holdings, which embrace ABB, As ...

KOTAK MAHINDRA BANK LIMITED 39 064 M $
Logo Kotak Mahindra Bank Limited

Kotak Mahindra Bank Limited is one of India's leading banking groups. Income (including intragroup) breaks down aby activity as follows: - life insurance (28.3%); - retail banking (23.8%); - corporate banking (21.2%); - market and investment banking ( ...

SHISEIDO COMPANY, LIMITED 11 913 M $
Logo Shiseido Company, Limited

Shiseido Company, Limited specializes in the design, manufacturing and marketing of cosmetics. The group offers beauty products (including makeup items, coloring, etc. ; Shiseido, Aupr's, DQ, Za, Revital Granas, B?n?fique, Maquillage and Elixir), skin car ...

SHISEIDO COMPANY, LIMITED 11 913 M $
Logo Shiseido Company, Limited

Shiseido Company, Limited specializes in the design, manufacturing and marketing of cosmetics. The group offers beauty products (including makeup items, coloring, etc. ; Shiseido, Aupr's, DQ, Za, Revital Granas, B?n?fique, Maquillage and Elixir), skin car ...

SAAB AB 11 076 M $
Logo Saab AB

Saab AB is a Sweden-based company offering products and services ranging from military defense to civil security. The Company’s operations are divided into six business areas. The Aeronautics includes the development of civil and military aviation techn ...

SAAB AB 11 076 M $
Logo Saab AB

Saab AB is a Sweden-based company offering products and services ranging from military defense to civil security. The Company’s operations are divided into six business areas. The Aeronautics includes the development of civil and military aviation techn ...

ASSEMBLY BIOSCIENCES, INC. 73 M $
Logo Assembly Biosciences, Inc.

Assembly Biosciences, Inc. is a biotechnology company, which is engaged in the development of small molecule antiviral therapeutics. The Company’s pipeline includes two helicase-primase inhibitors (HPI) targeting recurrent genital herpes, an orally bioa ...

DAR GLOBAL PLC 668 M $
Logo Dar Global PLC

Dar Global PLC is a United Kingdom-based company engaged in a differentiated international real estate business. The Company focuses predominantly on developing real estate projects comprising second homes for internationally mobile customers in locations ...

S. ROMAERO S.A. 24 M $
Logo S. Romaero S.A.

Romaero SA is a Romania-based company engaged in the aerospace industry. The Company is primarily involved in the maintenance, repair and modernization of civil and military aircrafts. Additionally, the Company produces aircraft components, including stru ...


123Next

Insiders


Picture Walid Abi-Saab
Walid Abi-Saab

Dr. Walid Abi-Saab, MD, is a Chief Medical Officer at Galapagos NV. Dr. Abi-Saab was previously employed as a Group Vice President-Clinical Development by Shire Plc and an Assistant Professor-Psychiatry & Neurosurgery by Yale School of Medicine. He received his doctorate degree from the University of Saint Joseph (Macau).


Picture Chakib Abi-Saab
Chakib Abi-Saab

Chakib Abi-Saab is currently the Chief Technology Officer at The National Shipping Co. of Saudi Arabia.
Previously, he worked as the Chief Information Officer at Bumi Armada Bhd.
from 2011 to 2014.
He also worked as a Member at Gartner Research Group.
Mr. Abi-Saab received his undergraduate degree and MBA from Letourneau University.








Picture Walid Mohammed Jamil Al-Jamal
Walid Mohammed Jamil Al-Jamal

Walid Mohammed Jamil Al-Jamal is currently the Vice Chairman & Chief Executive Officer at Jordan Decapolis Properties.
He is also the Chairman of Al Rashad Industrial Investments Co., Aman Jordan Decapolis.
For Tourism Investments Co., South Dead Sea Development Specialised Resort Co., Ahyaa Amman Real Estate Development Co., and Eagle Group International Investment Co. Additionally, he serves as a Non-Independent Non-Executive Director at Bank of Jordan and as a Director at Mediterranean & Gulf Insurance Co. Plc, Al Taher for Investment & Real Estate Development Co., Al Adaa For Real Estate Leasing & Development LLC, Ma'in Hot Springs Resort & Spa, and Spectra International For Colors & Plastics Ltd.
Previously, Mr. Al-Jamal worked as the Director-Finance & Administration at First Jordan Investment Co. from 2011 to 2013.
He completed his undergraduate degree at The University of Jordan in 1992 and obtained an MBA from the University At Buffalo in 1994.

No results for this search

-40% Limited Time Offer: Our subscriptions help you unlock hidden opportunities.
SIGN UP NOW